A statistically significant primary endpoint is the headline every biotech press release leads with, but it is also the least informative number for anyone trying to judge whether a drug will actually change clinical practice or move a company’s valuation.
The first thing worth checking is effect size, not just significance. A trial can hit its primary endpoint with a p-value well under 0.05 while showing a clinical benefit so small that physicians and payers will not consider it meaningful. Statistical significance answers whether an effect is real; it says nothing about whether the effect is large enough to matter.
Secondary endpoints deserve almost as much scrutiny as the primary one, particularly when they were pre-specified. A drug that hits its primary endpoint but misses on quality of life measures or a key secondary outcome often faces a harder path with prescribers, even after approval, because those secondary measures are frequently what physicians care about most in practice.
Subgroup analyses require particular caution. A strong effect in one subgroup within an otherwise flat overall trial is sometimes a genuine biological signal worth pursuing, and sometimes a statistical artifact from slicing the data enough ways that something eventually looks significant. The trial’s pre-specified statistical plan is the best guide to which case applies.
Safety data, often buried well below the efficacy tables, is where many readouts quietly turn from a win into a more complicated story. Discontinuation rates due to adverse events tell a more practical story than the adverse event list itself, since a drug with a strong efficacy signal but high discontinuation rates may struggle with real-world adherence regardless of what the topline numbers suggest.
Deep Dive coverage of individual trial readouts, the kind that walks through effect size, secondary endpoints, and safety data rather than repeating the press release, such as the analysis published by The Pharma Vanguard, gives investors and clinicians a more complete picture than the topline result alone ever can.
